万古霉素在儿科血液肿瘤患者中的应用。

Vancomycin use in pediatric hematology-oncology patients.

作者信息

Hopkins H A, Sinkowitz-Cochran R L, Rudin B A, Keyserling H L, Jarvis W R

机构信息

Hospital Infections Program, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services, Atlanta, Georgia 30333, USA.

出版信息

Infect Control Hosp Epidemiol. 2000 Jan;21(1):48-50. doi: 10.1086/501698.

DOI:10.1086/501698

PMID:10656357

Abstract

Across-sectional study was performed of pediatric hematology-oncology patients who received vancomycin; use was compared to the Centers for Disease Control and Prevention (CDC) recommendations for vancomycin use. Thirty-seven patients received 308 doses of vancomycin. AR patients initially received vancomycin as empirical therapy; 100% of this use was not consistent with the CDC recommendations.

摘要

对接受万古霉素治疗的儿科血液肿瘤患者进行了一项横断面研究；将用药情况与疾病控制和预防中心（CDC）的万古霉素使用建议进行了比较。37名患者接受了308剂万古霉素。AR患者最初接受万古霉素作为经验性治疗；这种用药情况100%不符合CDC的建议。